Dosage protocol · Skin & Cosmetic
SNAP-8 10 mg
Label and batch log: Record active mass, final weight, concentration, vehicle, pH, container, date, storage, and observations.
- Human schedule context: Twice-daily cream application for 28 days in manufacturer testing.
- Label and batch log: Record active mass, final weight, concentration, vehicle, pH, container, date, storage, and observations.
- Application context: Twice daily around the eye area for 28 days in manufacturer testing.
- Academic serum context: Morning and evening or twice-daily use for 12 weeks in multi-ingredient studies.
Reconstitution
SNAP-8 dosage chart
| Final Batch | Active Peptide | Active % w/w | ppm | Research Context |
|---|---|---|---|---|
| 30 g | 10 mg | 0.0333% w/w | 333 ppm | About 6.7 times the upper developer reference |
| 50 g | 10 mg | 0.0200% w/w | 200 ppm | 4 times the upper developer reference |
| 100 g | 10 mg | 0.0100% w/w | 100 ppm | 2 times the upper developer reference |
| 200 g | 10 mg | 0.0050% w/w | 50 ppm | Matches 10% of the nominal 0.05% supplier solution |
| 333.3 g | 10 mg | 0.0030% w/w | 30 ppm | Mid-range calculation |
| 666.7 g | 10 mg | 0.0015% w/w | 15 ppm | Matches 3% of the nominal 0.05% supplier solution |
| Final Batch | 0.0015% Active | 0.0030% Active | 0.0050% Active |
|---|---|---|---|
| 30 g | 0.45 mg | 0.90 mg | 1.50 mg |
| 50 g | 0.75 mg | 1.50 mg | 2.50 mg |
| 100 g | 1.50 mg | 3.00 mg | 5.00 mg |
| 200 g | 3.00 mg | 6.00 mg | 10.00 mg |
| Final Batch | Stock for 0.0015% | Stock for 0.0030% | Stock for 0.0050% |
|---|---|---|---|
| 30 g | 0.45 mL | 0.90 mL | 1.50 mL |
| 50 g | 0.75 mL | 1.50 mL | 2.50 mL |
| 100 g | 1.50 mL | 3.00 mL | 5.00 mL |
| Trade Solution | Peptide in Stock | Final Active % | Equivalent ppm |
|---|---|---|---|
| 3% | 0.05% | 0.0015% | 15 ppm |
| 6% | 0.05% | 0.0030% | 30 ppm |
| 10% | 0.05% | 0.0050% | 50 ppm |
| Study | Formulation | Schedule | Design Context | Evidence Limit |
|---|---|---|---|---|
| Lipotec developer panel [6] | Cream with 10% of a nominal 0.05% SNAP-8 solution, equal to about 0.005% active peptide | Twice daily around the eye area for 28 days | 17 women; silicone replicas and profilometry; about 35% mean and 63% maximum wrinkle-depth reduction reported | Manufacturer-reported, not an independent peer-reviewed trial |
| Shin et al. (2024) [1] | 350 micrometer dissolving patch with 0.03% SNAP-8, 5% AA2G, 4% cyclic LPA, and 90% HA | Overnight nightly through day 14, then every third day through day 28 | 24 enrolled and 21 completed a split-face active-versus-placebo comparison | Combination device; SNAP-8’s independent contribution cannot be isolated |
| Avcil et al. (2020) [2] | HA microneedle patch with SNAP-8, other peptides, adenosine, and seaweed extracts | 12-week study | Fine lines, hydration, dermal density, thickness, and tolerability measures | Multi-active product; SNAP-8 concentration was not disclosed in the abstract |
| Draelos et al. (2016) [3] | Multi-peptide serum containing SNAP-8 within a supporting skincare regimen | Morning and evening for 12 weeks after a 2-week washout | 29 women; investigator grading and participant questionnaires | Open label, no control, multiple peptides and supporting products |
| Moy et al. (2023) [4] | Proprietary multi-peptide facial serum containing acetyl octapeptide-3 | Twice daily for 12 weeks | 31 women completed dermatologist grading, imaging, hydration, and questionnaires | Uncontrolled, multi-ingredient, and company funded |
How much to draw
The Draw column shows exactly where to stop on a U-100 insulin syringe. Different vial size or dose? The calculator below recomputes it live.
Supplies needed
Supplies needed
Peptide vial
The lyophilized compound
Bacteriostatic water
For reconstitution
U-100 insulin syringes
One per injection
Alcohol swabs
Stopper + site each time
How it works
SNAP-8 is a synthetic octapeptide (eight amino acids) most commonly identified by its INCI ingredient name, acetyl octapeptide-3.[1] It is formulated into topical cosmetic products — serums and creams — aimed at softening the appearance of expression lines and wrinkles, and it is a close chemical relative of Argireline (acetyl hexapeptide-8), an earlier cosmetic peptide built around the same signaling concept.
Unlike the injectable research peptides discussed elsewhere on this site, SNAP-8 is fundamentally a cosmetic-industry ingredient, not a systemic or injectable compound. It is regulated as a cosmetic ingredient rather than as a drug, and its evidence base and safety profile should be understood in that context rather than compared directly to prescription peptide therapies.[2]
Benefits & side effects
Peer-reviewed human evidence specific to SNAP-8 is limited. Most of the supporting science comes from research on the related peptide Argireline, which has published human anti-wrinkle data, and from broader reviews of cosmeceutical peptides that describe promise but also note challenges with formulation, skin penetration, and inconsistent clinical validation.[5]
Online claims citing specific figures — for example, wrinkle-depth reductions of "up to 63 percent" — trace back to particular studies or manufacturer data whose protocols, concentrations, and funding are not always transparent, and should not be generalized to every SNAP-8-containing product. The most defensible summary is that SNAP-8 sits in an early, evidence-limited cosmetic category, supported more by analogy to Argireline than by direct, high-quality trials of SNAP-8 itself.
Calculator
Plan your own dose
Reconstituting a different vial size or targeting a different dose? Run the numbers.